Stryker Corporation, a global leader in medical technology, reported its second-quarter 2026 financial results on Thursday, revealing a complex picture of significant revenue growth tempered by persistent operational hurdles. Despite navigating the lingering aftermath of a devastating cyberattack that paralyzed its operations earlier this year and grappling with a new supply chain disruption within its recently acquired Inari Medical business, the Kalamazoo-headquartered firm posted a 9.4% increase in revenue, reaching $6.6 billion for the quarter. Net earnings saw a dramatic surge of 44.3% year-over-year to $1.3 billion, a figure bolstered significantly by one-time tariff refunds.
The quarterly performance highlights the resilience of the medical device giant as it attempts to stabilize its manufacturing and logistics infrastructure. CEO Kevin Lobo and CFO Preston Wells addressed investors in an afternoon earnings call, detailing the company’s roadmap for clearing a massive order backlog and reinforcing its digital defenses following the March 2026 security breach.
A Chronology of the 2026 Cyber Crisis
The defining event of Stryker’s 2026 fiscal year began in early March when a sophisticated cyberattack, reportedly linked to international threat actors, forced the company to take its order processing, shipping, and manufacturing systems offline. For nearly a month, the company’s global operations were severely restricted, leading to a significant "miss" in the first quarter and a cascading effect on its delivery timelines.
By April, Stryker had begun the painstaking process of restoring its IT infrastructure and validating its manufacturing protocols. However, the outage left the company with a "tremendous number of orders" that could not be fulfilled during the downtime. Throughout the second quarter, Stryker focused on ramping up production capacity across its global facilities, particularly in its MedSurg and Neurotechnology divisions.
Lobo informed investors that while the recovery is well underway, the company is still in the "catch-up" phase. The CEO projected that the order backlog would return to a "manageable level" by the end of the third quarter, though he acknowledged that the recovery timeline varies across different product categories.
Financial Performance: By the Numbers
Stryker’s financial health remained robust despite the operational friction. The $6.6 billion in Q2 revenue represents a strong recovery from the stagnant growth seen in the immediate wake of the cyberattack. The 9.4% year-over-year increase suggests that underlying demand for Stryker’s orthopedic implants, robotic systems, and surgical tools remains high.
The 44.3% increase in net earnings to $1.3 billion was the standout figure of the report. CFO Preston Wells clarified that this spike was not purely organic; it was aided by substantial tariff refunds related to international trade adjustments. However, even when adjusting for these windfalls, the company’s profitability remained resilient.
The company’s growth was distributed across several key segments:
- MedSurg and Neurotechnology: This segment saw continued demand for capital equipment, though it was the area most affected by the manufacturing delays.
- Orthopaedics and Spine: Growth in elective procedures globally continued to drive demand for Stryker’s Mako robotic-arm assisted surgery platforms and associated implants.
Despite these gains, Wells noted that the company continues to face headwinds. The costs associated with the cyberattack remediation—including IT forensic charges, system upgrades, and manufacturing inefficiencies—continue to weigh on the balance sheet. Furthermore, the rising costs of raw materials and oil have added pressure to the company’s operating margins.
The Manufacturing Bottleneck: Medical Beds and Capital Equipment
One of the most significant challenges cited by Lobo involves the production of medical beds and other large-scale capital equipment. Unlike smaller disposable instruments, medical beds require complex assembly lines and extensive logistical planning.
"Making beds takes time, and we were out of production for a long period of time," Lobo told investors. The CEO explained that the sheer volume of the backlog meant that even with factories running at maximum capacity, the lead times for hospital customers remain longer than historical averages.
This delay in capital equipment delivery is a critical metric for analysts, as it represents "locked-in" revenue that has yet to be recognized. Lobo emphasized that the demand is not the issue—the orders are already on the books. The challenge remains purely a matter of execution: manufacturing the units and shipping them to healthcare facilities that are eager to upgrade their infrastructure.
Inari Medical and New Supply Chain Disruptions
While the company worked to move past the cyberattack, a new complication emerged regarding Inari Medical. Stryker acquired Inari Medical in late 2025 for approximately $4.9 billion, a move intended to bolster its presence in the high-growth venous thromboembolism (VTE) market. Inari is well-known for its innovative thrombectomy systems, which are used to mechanically remove blood clots from the peripheral reproductive system.
During the earnings call, Lobo revealed that Stryker is currently managing a significant supply disruption related to Inari. While he did not provide exhaustive details regarding the root cause, he pointed to an issue at a primary manufacturing plant that produces the majority of Inari’s product portfolio. This disruption has resulted in significant backorders for thrombectomy devices, complicating the integration of the new business unit.
The Inari situation highlights the risks associated with manufacturing concentration. As Stryker works to resolve the plant-specific issues, it must also reassure clinicians who rely on these life-saving devices for emergency procedures. Lobo expressed confidence that the disruption is temporary but admitted it has dampened the immediate contribution of the Inari acquisition to the second-quarter results.
Revised 2026 Outlook and Market Reaction
In light of the ongoing recovery and the Inari supply issues, Stryker has narrowed its organic sales growth forecast for the full year 2026. The company now expects growth in the range of 8.3% to 9.3%, a slight tightening from the previous guidance of 8% to 9.5%.
This adjustment reflects a balanced view of the remainder of the year. While the company expects a strong third and fourth quarter as backlogs are cleared, the uncertainties surrounding supply chain stability and the final costs of cyber remediation suggest a more conservative ceiling for growth.
Market analysts have expressed a mix of optimism and caution. BTIG analyst Ryan Zimmerman noted in a research brief that while the second-quarter numbers were "solid under the circumstances," the pressure is now on the fourth quarter to deliver the bulk of the year’s growth. "The onus falls to the fourth quarter to prove that the manufacturing engine is fully back on track," Zimmerman wrote.
Lobo remains undeterred by the skepticism. "Honestly, on a $25 billion business, to be growing at around the 9% range, it’s still a pretty good year, given that we were knocked out for almost an entire month," he told investors.
Broader Implications for the MedTech Industry
Stryker’s experience in 2026 serves as a cautionary tale for the broader medical technology industry. The March cyberattack underscores the extreme vulnerability of global supply chains to digital disruption. As medical device companies become increasingly reliant on interconnected ERP systems and automated manufacturing, the "blast radius" of a single security breach can extend for months, affecting patient care and hospital operations worldwide.
Furthermore, the supply disruption at Inari Medical points to the ongoing volatility in global manufacturing. Even as the world moves further away from the disruptions of the COVID-19 pandemic, localized issues—whether technical, regulatory, or logistical—can still create significant bottlenecks for specialized medical products.
Stryker’s ability to maintain nearly 10% revenue growth despite these "black swan" events is a testament to the essential nature of its products. Hospitals cannot easily pivot away from established surgical platforms like Mako or specialized trauma implants, providing Stryker with a degree of "revenue stickiness" that few other industries enjoy.
Looking Ahead
As Stryker enters the second half of 2026, its primary focus will be twofold: operational stabilization and digital fortification. The company is expected to invest heavily in redundant manufacturing capabilities and enhanced cybersecurity protocols to prevent a recurrence of the March outage.
Investors will be watching closely to see if the Inari Medical supply issues are resolved by the Q3 earnings report and whether the medical bed backlog is indeed reduced to "manageable levels." If Stryker can execute its plan to clear the order book, the company may end 2026 as one of the most resilient performers in the healthcare sector, having survived a "perfect storm" of digital and physical operational challenges.
For now, the message from Stryker leadership is one of cautious confidence. The demand for medical innovation remains at an all-time high, and for a company of Stryker’s scale, the path forward is clear: manufacture, ship, and secure.
